Fresh from the pipeline: Aflibercept

Nature Reviews Drug Discovery

Volumn 11, Issue 4, 2012, Pages 269-270

  Stewart, Michael W ^a   Grippon, Seden ^b   Kirkpatrick, Peter ^c  

^a MAYO CLINIC   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; EYLEA; PEGAPTANIB; RANIBIZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VERTEPORFIN; HYBRID PROTEIN;

ANTIANGIOGENIC ACTIVITY; BLINDNESS; COST CONTROL; DIABETIC RETINOPATHY; DRUG APPROVAL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; HUMAN; LASER COAGULATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RETINA MACULA AGE RELATED DEGENERATION; SHORT SURVEY; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; DOUBLE BLIND PROCEDURE; EXUDATIVE MACULAR DEGENERATION; FOOD AND DRUG ADMINISTRATION; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED STATES;

CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT FUSION PROTEINS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WET MACULAR DEGENERATION;

EID: 84859345388     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3700     Document Type: Short Survey

References (5)

1. Stewart, M. W. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin. Proc. 87, 77-88 (2012).
2. Narayanan, R. et al. Ranibizumab. Nature Rev. Drug Discov. 5, 815-816 (2006).
3. Holash J. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA 99, 11393-11398 (2002).
4. US Food and Drug Administration. FDA labeling information - Eylea. FDA website [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 125387lbl.pdf (2011).
5. Martin, D. F. et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364,1897-1908 (2011).